Measles is spreading in 91% of Bangladesh's districts after a two-year vaccine stockout
WHO reports 19,161 suspected cases and 166 deaths in a single month, most in children under five. The country had been close to eliminating the disease.
Bangladesh spent two decades pushing measles towards elimination. A one-month snapshot of the reversal is now on the record.
On 4 April 2026, Bangladesh's national International Health Regulations focal point notified WHO of a nationwide increase in measles, affecting 58 of the country's 64 districts — 91% — across all eight divisions [s1]. Between 15 March and 14 April, the country reported 19,161 suspected measles cases and 166 measles-related deaths, a case fatality ratio of 0.9% [s1]. Seventy-nine percent of reported cases were children under five [s1].
WHO assesses the risk at national level as high, and at regional level as high [s1]. Globally it is rated moderate [s1].
What the numbers say, and where they disagree
WHO's own summary and its detailed description give slightly different confirmation counts for the same period: the situation-at-a-glance section reports 2,897 laboratory-confirmed cases, while the description of the situation reports 2,973 [s1]. Both figures cover 15 March to 14 April. The gap is small and almost certainly reflects a moving laboratory backlog rather than a discrepancy of substance, but it is worth naming, because it is a reminder that outbreak figures reported this early are provisional.
The deaths are recorded two ways. There are 166 suspected measles-related deaths at a CFR of 0.9%, and 30 laboratory-confirmed deaths at a CFR of 1.1% [s1]. Confirmed deaths are a subset, counted against a smaller confirmed-case denominator — which is why the confirmed CFR is higher, not because confirmed cases are more lethal.
The hospital load is substantial: 12,318 admissions and 9,772 discharges in the same window [s1].
Where it is concentrated
Dhaka division carries the heaviest burden with 8,263 suspected cases, followed by Rajshahi (3,747), Chattogram (2,514) and Khulna (1,568) [s1]. Within Dhaka, cases are concentrated in densely populated informal settlements — WHO names Demra, Jatrabari, Kamrangirchar, Korail, Mirpur and the Tejgaon industrial and slum clusters [s1].
The age distribution is the part that determines how bad this gets. Children under five account for 79% of reported cases, children under two for 66%, and infants under nine months — too young for the first scheduled dose — for 33% [s1]. Deaths have occurred mainly among unvaccinated children under two [s1]. WHO's risk assessment separately notes that 91% of cases occurred among children aged 1 to 14, indicating substantial immunity gaps across that whole band [s1]. The two figures are computed on different age groupings and are not in conflict; together they describe an outbreak that is hitting the youngest hardest but is not confined to them.
Why immunity fell
This is not a story about a population that never had coverage. It is a story about coverage that was built and then lost.
Reported coverage with the first dose of measles-containing vaccine rose from 89% in 2000 to 118% in 2016 on the WUENIC estimates WHO cites; second-dose coverage rose from 22% at its nationwide introduction in 2012 to 121% in 2024 [s1]. (Administrative coverage figures above 100% reflect denominator problems — vaccinating more children than the population estimate says exist — not over-vaccination.) Confirmed measles incidence declined sharply across the same period [s1].
Three things then went wrong at once, on WHO's account: a nationwide stockout of measles-rubella vaccine across 2024 and 2025 pushed first- and second-dose coverage down; routine immunisation gaps persisted; and no regular nationwide supplementary measles-rubella campaign had been run since 2020 [s1]. Supplementary campaigns are the mechanism that catches children missed by routine services. Six years without one, on top of a supply failure, accumulates a susceptible cohort.
Measles is unusually unforgiving of this. It is among the most transmissible human pathogens, and sustained interruption generally requires roughly 95% coverage with both doses, held evenly across every municipality rather than averaged nationally [s1].
The response
Bangladesh's National Immunization Technical Advisory Group approved a nationwide measles-rubella campaign on 30 March 2026, targeting children aged 6 to 59 months with expanded coverage down to 6–8 months [s1]. It began on 5 April in 30 upazilas across 18 priority districts, and went nationwide on 20 April [s1].
Alongside that: district rapid response teams activated, vaccine procurement fast-tracked by the Ministry of Health, vitamin A supplementation provided to all suspected and confirmed cases as part of standard case management, isolation capacity strengthened, and hospital infection prevention and control reinforced [s1]. There is no specific antiviral treatment for measles [s1].
What to watch
Cross-border spread is the explicit regional concern. Bangladesh shares long land borders with India and Myanmar [s1]. WHO notes that Myanmar has a considerable number of zero-dose children with surveillance and response capacity limited by ongoing conflict, and that India, despite high vaccination coverage, has reported a rise in case counts over the preceding six months [s1]. High-incidence Bangladeshi cities including Jashore and Chapainawabganj — the latter identified as a hotspot — sit on busy land crossings with India [s1]. Dhaka, Chattogram, Sylhet and Cox's Bazar are international transit hubs [s1].
Measles is endemic across WHO's South-East Asia region, which is why the regional risk rating matches the national one [s1].
The near-term question is whether the nationwide campaign closes the gap fast enough to break transmission before the susceptible pool refills — and whether MR vaccine supply, the proximate cause of the coverage decline, is now secure. WHO's assessment is blunt: continued spread is likely unless surveillance, rapid detection and vaccination activities close the immunity gaps [s1].
WHO does not recommend any travel or trade restriction based on the information available [s1].
This article is informational and does not constitute medical advice.
Sources
- [s1] World Health Organization, "Measles - Bangladesh" (Disease Outbreak News), 23 April 2026. https://www.who.int/emergencies/disease-outbreak-news/item/2026-DON598
Sources
- Measles - Bangladesh (Disease Outbreak News) — World Health Organization , April 23, 2026
More on
WHO closes 2025 with 96 countries measles-free and a warning about new vaccine financing
The year-end immunization summary reports 88% fewer measles deaths since 2000, malaria vaccine in 24 African countries, and 25 years without wild polio in the Western Pacific.
Lebanon investigated only 52% of suspected measles cases adequately, a review finds
An analysis of a decade of surveillance data shows the system leans heavily on hospitals and misses cases in the community — the weakness that lets measles circulate undetected between outbreaks.
The US is likely to lose its measles elimination status this fall. What that means.
A ruling comes in November. The country has held the status since 2000, and 2026 has already produced more cases than any year in three decades.
The US matched last year's entire measles case count — with six months of 2026 still to go
CDC data through July 2 puts 2026 at 2,170 confirmed cases, just short of all of 2025's 2,289. Ninety-three percent of this year's cases are linked to active outbreaks.